Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT07696663
Starting soon Not applicable

Balance Dimensions-Based Rehabilitation Program in People With Acquired Brain Injury

NCT07696663 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2026-09
Last updated
2026-07-10

Condition(s) studied

Acquired Brain InjuryBalance Disorders

Investigational drug(s) / intervention(s)

Multimodal Balance Rehabilitation ProgramConventional Physiotherapy

Multimodal Balance Rehabilitation Program: A multimodal rehabilitation program based on balance dimensions designed to improve balance performance in people with acquired brain injury.

Conventional Physiotherapy: Conventional physiotherapy routinely provided at CEADAC according to standard clinical practice.

Study summary

The purpose of this clinical trial is to find out whether a rehabilitation program based on different dimensions of balance can improve balance, mobility, walking ability, and quality of life in people with acquired brain injury.

The main questions this study aims to answer are:

* Does this rehabilitation program improve balance?
* Does it improve mobility and walking ability?
* Does it reduce the risk of falls?
* Does it improve quality of life?

Researchers will compare a specific balance rehabilitation program with conventional physiotherapy to determine whether the balance program provides additional benefits.

Participants with acquired brain injury who meet the eligibility criteria will be randomly assigned to one of two groups. Both groups will receive treatment for 12 weeks.

Participants will:

* Complete balance and mobility assessments before starting treatment.
* Receive either the balance rehabilitation program or conventional physiotherapy five times per week.
* Complete assessments immediately after treatment and again 6 and 12 weeks later.

The information obtained from this study may help improve rehabilitation programs and daily functioning for people with acquired brain injury.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18 to 65 years. * Diagnosis of acquired brain injury (stroke, traumatic brain injury, anoxic brain injury, brain tumor, or encephalitis). * At least 2 months since the brain injury. * Mini-Mental State Examination (MMSE) score greater than 24. * Modified Rankin Scale (mRS) score of 3 or lower. * Ability to walk independently or with an assistive device. * Clinical stability and ability to participate in a rehabilitation program. * Written informed consent signed by the participant. Exclusion Criteria: * Severe cognitive impairment (MMSE score of 24 or lower). * Severe functional dependence (mRS score greater than 3). * Unstable medical conditions that may interfere with participation. * Severe musculoskeletal, cardiovascular, or other conditions that prevent safe participation in the intervention. * Severe communication disorders that prevent understanding of study procedures. * Participation in another clinical trial that may interfere with the study results.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Centro de Referencia Estatal de Atención al Daño Cerebral (CEADAC) Madrid Madrid

More University of Castilla-La Mancha trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07696663 on ClinicalTrials.gov ↗ ← All trials in Spain